Valuation: Charles River Laboratories International, Inc.

Market Cap 15.06B 13.72B 12.64B 11.5B 21.57B 1,395B 22.67B 154B 61.14B 762B 56.51B 55.32B 2,391B P/E 2026 *
35.7x
P/E 2027 * 33.4x
Enterprise Value 17.09B 15.57B 14.34B 13.05B 24.48B 1,583B 25.73B 175B 69.39B 864B 64.13B 62.78B 2,713B EV / Sales 2026 *
4.32x
EV / Sales 2027 * 4.09x
Free-Float
95.88%
Yield 2026 *
-
Yield 2027 * -
11-20 Baird Adjusts Price Target on Charles River Laboratories to $365 From $364 MT
11-12 Charles River Laboratories International, Inc. Expands Global Microbial Solutions Network Through Investments in Manufacturing, Customer Support, and Sustainability CI
11-12 TD Cowen Adjusts Price Target on Charles River Laboratories International to $388 From $325 MT
11-12 TD Cowen Adjusts Charles River Laboratories Price Target to $388 From $325, Maintains Buy Rating MT
11-11 Analyst recommendations: Apple, Diamondback Energy, Vertiv Holdings, Coreweave… Zonebourse
11-10 Frontage Agrees to Take-Private Offer MT
11-09 HK-listed Frontage to be taken private in $616 million deal backed by Charles River RE
11-09 Charles River to Acquire Frontage Bioanalysis, DMPK Businesses for $470 Million MT
11-09 Deals of the day-Mergers and acquisitions RE
11-09 Charles River Laboratories International, Inc., Hongkong Tigermed Consulting Co., ltd. and Song Li, Chairman of the Board of Frontage Holdings Corporation agreed to acquire remaining 26.65% stake in Frontage Holdings Corporation. CI
11-09 Charles River Laboratories International, Inc. (NYSE : CRL) entered into definitive agreements to acquire Bioanalysis and DMPK operations in Exton, Pennsylvania of Frontage Holdings Corporation (SEHK : 1521) for $545 million. CI
11-06 UBS Adjusts Price Target on Charles River Laboratories International to $387 From $357, Maintains Buy Rating MT
11-06 Rothschild & Co Redburn Adjusts Price Target on Charles River Laboratories International to $375 From $318 MT

Last Transcript: Charles River Laboratories International, Inc.

1 day-4.15%
1 week-7.00%
Current month-12.55%
1 month-0.36%
3 months+7.85%
6 months+101.45%
Current year+57.57%
1 week 310.52
Extreme 310.52
343.57
1 month 310.52
Extreme 310.52
379.63
Current year 146.2
Extreme 146.195
379.63
1 year 146.2
Extreme 146.195
379.63
3 years 91.86
Extreme 91.8609
379.63
5 years 91.86
Extreme 91.8609
385.1
10 years 69.51
Extreme 69.51
460.21
Manager TitleAgeSince
Chief Executive Officer 56 05/05/2026
Director of Finance/CFO 58 06/04/2026
Chief Tech/Sci/R&D Officer 45 12/01/2026
Director TitleAgeSince
Chairman 75 01/01/2000
Director/Board Member 56 05/05/2026
Chairman 69 05/05/2026
Date Insider Type Main position Quantity % Market Cap. Importance
22/10/26 Exercice

Director

72,126 0.1511%
21/10/26 Exercice

Executive/Senior Manager

6,468 0.0135%
5/10/26 Exercice

Executive/Senior Manager

2,943 0.0062%
Change 5-day change 1-year change 3-year change Capi.($)
-4.15%-7.00%+93.93%+64.97% 15.06B
-2.49%-3.76%+50.31%+62.10% 63.66B
-0.63%-2.91%+6.20%+89.22% 58.56B
-2.37%-2.22%+22.87%+82.31% 54.19B
-2.19%-6.15%+11.92%+108.08% 44.66B
-1.89%-7.28%+13.22%+19.74% 40.51B
-0.93%-0.47%+19.73%+43.75% 36.27B
+1.11%-6.44%+130.68%+641.83% 34.89B
-0.80%+0.61%+77.26%+56.26% 32.26B
-2.17%+16.65%-29.21%+474.05% 31.01B
Average -1.65%-1.47%+39.69%+164.23% 41B
Weighted average by Cap. -1.58%-1.92%+34.42%+147.75%

Financials

2026 *2027 *
Net sales 3.95B 3.6B 3.32B 3.02B 5.66B 366B 5.95B 40.37B 16.05B 200B 14.83B 14.52B 627B 4.06B 3.7B 3.41B 3.1B 5.81B 376B 6.11B 41.46B 16.48B 205B 15.23B 14.91B 644B
Net income 423M 385M 355M 323M 606M 39.18B 637M 4.32B 1.72B 21.4B 1.59B 1.55B 67.16B 431M 392M 362M 329M 617M 39.89B 648M 4.4B 1.75B 21.79B 1.62B 1.58B 68.38B
Net Debt 2.03B 1.85B 1.7B 1.55B 2.91B 188B 3.06B 20.74B 8.24B 103B 7.62B 7.46B 322B 1.55B 1.41B 1.3B 1.18B 2.22B 143B 2.33B 15.8B 6.28B 78.25B 5.8B 5.68B 246B
Projected Income Statement - Annual - Charles River Laboratories International, Inc.
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (59.8%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (21.1%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19.1%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (80.9%) and sales of products (19.1%). Net sales are distributed geographically as follows: the United States (53.3%), Europe (27.5%), Canada (12.5%), Asia/Pacific (5.1%), and other (1.6%).
Employees
19,000
Date Price Change Volume
20/11/26 US$314.32 -4.15% 1,154,126
19/11/26 US$327.93 -1.60% 495,099
18/11/26 US$333.25 +0.33% 516,509
17/11/26 US$332.16 -1.00% 697,548
16/11/26 US$335.52 -0.72% 693,841
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Charles River Laboratories International, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
314.32USD
Average target price
350.64USD
Spread / Average Target
+11.56%